CMS reinstates former albuterol HCPCS codes as part of first quarter update

Why This Topic Matters

Organizations that bill HCPCS services need to track quarterly updates so claims and charge capture reflect current CMS status. The article helps readers understand which parts of the update may affect respiratory therapy, orthotics, immune globulin, iron dextran, and related outpatient reporting.

Article Sections

1. HCPCS first-quarter update overview

   Introduces the CMS quarterly update and the general scope of the HCPCS changes taking effect on the stated date. It also identifies the specialties most likely to notice the update.

2. Respiratory inhalation drug code reinstatement

   Covers the temporary status change involving respiratory drug reporting and the reinstatement of earlier HCPCS entries. The section focuses on the update context for albuterol and levalbuterol services.

3. Other HCPCS code and modifier changes effective April 1

   Summarizes additional HCPCS update items beyond the respiratory drug changes, including a modifier revision and several newly added or status-referenced codes. It presents the broader administrative update categories without detailed coding guidance.